secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K/A
Filed at:   2022-10-31T23:59:59+00:00
Accession:  0001193125-22-273298
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha grants Astellas options for GAN/Rett programs; $20M upfront + $30M equity raise
--------------------------------------------------------------------------------

- Astellas gets exclusive options to license TSHA-120 (GAN) and TSHA-102 (Rett) post specified clinical/regulatory milestones.
- Upfront payment of $20M from Astellas; $30M private placement of 7.27M shares of common stock at ~$4.13/share.
- TSHA-120 Type B end-of-Phase 2 FDA meeting scheduled Dec 13, 2022; update expected mid-Jan 2023.
- TSHA-102 preliminary safety/efficacy data for adult cohort now expected H1 2023 (delayed from year-end 2022); female pediatric trial to start H1 2023.
- Taysha agrees to change-of-control restrictions during Rett option period; Astellas receives board observer right.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312522273298/0001193125-22-273298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312522273298/d395338d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-273298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer